Venetoclax Monotherapy 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Venetoclax Monotherapy 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.	3
Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax